SecBot SecBot
SECBOTREPLAY Home › Report › TRVI

TRVI · Trevi Therapeutics announced positive feedback from its End-of-Phase 2…

Trevi Therapeutics, Inc. · PRESS-RELEASE filed Mar 9, 2026 at 07:30 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed Mar 9, 2026 at 07:30 ET

Trevi Therapeutics announced positive feedback from its End-of-Phase 2 meeting with the FDA, confirming the development path for Haduvio™ (nalbuphine ER) in IPF-related chronic cough. The company plans to initiate two parallel Phase 3 trials in 2026, marking a significant step toward a potential NDA submission for a condition with no approved therapies.

  • FDA alignment achieved on Phase 3 trial design and remaining development program for nalbuphine ER in IPF-related chronic cough
  • Two pivotal Phase 3 trials planned: one with ~300 patients (52-week dosing, primary endpoint at 24 weeks), another with ~130 patients (12-week dosing)
  • First Phase 3 trial on track to initiate in Q2 2026, second in H2 2026
  • Primary endpoint for both trials: relative change in 24-hour cough frequency vs. placebo using objective cough monitoring

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access